1. Home
  2. CRDL vs LPSN Comparison

CRDL vs LPSN Comparison

Compare CRDL & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • LPSN
  • Stock Information
  • Founded
  • CRDL 2017
  • LPSN 1995
  • Country
  • CRDL Canada
  • LPSN United States
  • Employees
  • CRDL N/A
  • LPSN N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • LPSN EDP Services
  • Sector
  • CRDL Health Care
  • LPSN Technology
  • Exchange
  • CRDL Nasdaq
  • LPSN Nasdaq
  • Market Cap
  • CRDL 126.5M
  • LPSN 105.3M
  • IPO Year
  • CRDL N/A
  • LPSN 2000
  • Fundamental
  • Price
  • CRDL $1.05
  • LPSN $0.97
  • Analyst Decision
  • CRDL Strong Buy
  • LPSN Hold
  • Analyst Count
  • CRDL 2
  • LPSN 1
  • Target Price
  • CRDL $9.00
  • LPSN N/A
  • AVG Volume (30 Days)
  • CRDL 1.2M
  • LPSN 2.5M
  • Earning Date
  • CRDL 08-14-2025
  • LPSN 11-06-2025
  • Dividend Yield
  • CRDL N/A
  • LPSN N/A
  • EPS Growth
  • CRDL N/A
  • LPSN N/A
  • EPS
  • CRDL N/A
  • LPSN N/A
  • Revenue
  • CRDL N/A
  • LPSN $271,750,000.00
  • Revenue This Year
  • CRDL N/A
  • LPSN N/A
  • Revenue Next Year
  • CRDL N/A
  • LPSN N/A
  • P/E Ratio
  • CRDL N/A
  • LPSN N/A
  • Revenue Growth
  • CRDL N/A
  • LPSN N/A
  • 52 Week Low
  • CRDL $0.77
  • LPSN $0.61
  • 52 Week High
  • CRDL $2.63
  • LPSN $2.08
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 39.49
  • LPSN 48.47
  • Support Level
  • CRDL $1.12
  • LPSN $0.88
  • Resistance Level
  • CRDL $1.14
  • LPSN $0.93
  • Average True Range (ATR)
  • CRDL 0.07
  • LPSN 0.07
  • MACD
  • CRDL -0.00
  • LPSN -0.02
  • Stochastic Oscillator
  • CRDL 5.56
  • LPSN 45.45

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.

Share on Social Networks: